Liftstream is an executive search recruitment company in the life sciences sector
Liftstream Attending World Orphan Drug Congress in Geneva
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Cydan, David Mott, Duchenne Muscular Dystrophy, funding, Liftstream, NEA, Orphan drugs, Prosensa, PTC Therapeutics, public private funding, Rare Disease, Sarepta, Shire, Summit, venture capital, Viropharma, WODC, world orphan drug congress
Leave a comment
Massachusetts biotech continues to excite with new investments
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Abingworth Management, BioPharma America, Biotechnology cluster, Boston, Brookside Capital, Cristina Csimma, Cydan, David Mott, Deerfield, DELPHI, Dicer Substrate siRNA, Dicerna Pharmaceuticals, drug delivery technologies, Duchenne Muscular Dystrophy, EDI200, Edimer Pharmaceuticals, EnCore™, exon skipping, Exportin-1, Forsite Capital Management, Genzyme, Inhibitors of Nuclear Export, innovation, investors, Karyopharm Therapeutics, Massachusetts, Neil Kirby, New Enterprise Associates, New Leaf Venture Partners, NEZ, Omega Funds, oncology market, Orphan Drug, Prosensa, RA Capital, Rare Disease, Sanofi, Series B, SR One, Third Rock Ventures, TKT, undruggable disease, Vertex Pharmaceuticals, X-linked Hypohidrotic Ectodermal Dysplasia, XLHED
Leave a comment
David Motts’ NEA weighs in on rare diseases
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged AstraZeneca, Cambridge MA, Clarus Ventures, Cydan, David Mott, DMD, Dr. Cristina Csimma, Duchenne Muscular Dystrophy, GSK, International Rare Diseases Research Consortium, James McArthur, MedImmune, NEA, Orphan Drug, orphan drug accelerator, Prosensa, Rare Disease, Treat-NMD, Virdante Pharmaceuticals, Wyeth
Leave a comment